Stockholm’s Pixelgen Technologies secures €13.26 million to advance spatial mapping of cell-surface proteins

Pixelgen Technologies, a Stockholm-based life sciences company that claims to have developed the first high-throughput platform for mapping molecular cell architecture, has closed an over26 million ($15.5 million) Series B funding round.  The round was led by new investor Flat Capital, with continued participation from existing investors Industrifonden and Navigare Ventures. Alongside the financing, Pixelgen is adding Flat Capital CEO Rickard El Tarzi and life sciences veteran Ramon Felciano, Ph.D., to its board of directors. “This financing gives us the resources to expand globally as demand grows for our Proxiome Kit and our data analysis and visualisation software. We’re proud to have Flat Capital join us and to have the continued confidence of Navigare and Industrifonden. Their support will help accelerate our commercial reach, grow our team and product portfolio, and bring molecular cell architecture to more researchers and new applications,” said Pixelgen CEO and co-founder Simon Fredriksson, PhD.  Pixelgen Technologies was founded in 2020 by Fredriksson, Alvaro Martinez Barrio, Ph.D., Fredrik Dahl, Ph.D., and Filip Karlsson. It emerged from stealth in December 2022 following the close of an approximate €5.13 million ($6 million) Seed round, led by Navigare Ventures.  Pixelgen Technologies helps researchers move beyond abundance measurements to capture the architectural features of cell state, disease and treatment response across immunology, haematology, oncology and cell therapy.  The company states that its Proxiome Kit is the first platform to enable high-throughput mapping of molecular cell architecture at nanoscale resolution. This provides researchers with a novel way to study cell function and disease mechanisms.  Pixelgen explains that while conventional proteomic approaches primarily measure protein abundance, the Proxiome Kit reveals how proteins are organised, clustered and localised on the surface of individual cells. It has also developed the Proximity Network Assay, a technology that enables high-dimensional analysis of cell surface architecture in single cells. Powered by the Proximity Network Assay, the Proxiome Kit enables researchers to investigate architectural features of cell state, disease and treatment response that are not captured by abundance measurements alone. “Pixelgen’s technology gives researchers the ability to study disease mechanisms and identify novel biomarkers in an entirely new way. We believe this could open new avenues for research in cancer, immunology and autoimmune disease, while broadening our understanding of basic biology. Pixelgen’s leadership team has successfully commercialised multiple life sciences products globally, and we look forward to supporting the company through its next phase of growth,” said Rickard El Tarzi, CEO of Flat Capital. The company plans to use this capital to accelerate global commercialisation of its Proxiome Kit and expand its presence in key markets. In June 2025, Pixelgen announced that it had been awarded a grant and equity financing of €12.5 million ($14.7 million) from the European Innovation Council (EIC) Accelerator. In October 2023, the company announced that it had closed a Series A financing of approximately €6.24 million ($7.3 million), led by new investor Industrifonden and Navigare Ventures, an investor in Pixelgen’s Seed round.  The post Stockholm’s Pixelgen Technologies secures €13.26 million to advance spatial mapping of cell-surface proteins appeared first on EU-Startups.